Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy

Background—Transfusional therapy for thalassemia major and sickle cell disease can lead to iron deposition and damage to the heart, liver, and endocrine organs. Iron causes the MRI parameters T1, T2, and T2* to shorten in these organs, which creates a potential mechanism for iron quantification. However, because of the danger and variability of cardiac biopsy, tissue validation of cardiac iron estimates by MRI has not been performed. In this study, we demonstrate that iron produces similar T1, T2, and T2* changes in the heart and liver using a gerbil iron-overload model. Methods and Results—Twelve gerbils underwent iron dextran loading (200 mg · kg−1 · wk−1) from 2 to 14 weeks; 5 age-matched controls were studied as well. Animals had in vivo assessment of cardiac T2* and hepatic T2 and T2* and postmortem assessment of cardiac and hepatic T1 and T2. Relaxation measurements were performed in a clinical 1.5-T magnet and a 60-MHz nuclear magnetic resonance relaxometer. Cardiac and liver iron concentrations rose linearly with administered dose. Cardiac 1/T2*, 1/T2, and 1/T1 rose linearly with cardiac iron concentration. Liver 1/T2*, 1/T2, and 1/T1 also rose linearly, proportional to hepatic iron concentration. Liver and heart calibrations were similar on a dry-weight basis. Conclusions—MRI measurements of cardiac T2 and T2* can be used to quantify cardiac iron. The similarity of liver and cardiac iron calibration curves in the gerbil suggests that extrapolation of human liver calibration curves to heart may be a rational approximation in humans.

[1]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[2]  S. Huffel,et al.  Anticipation of epileptic seizures from standard EEG recordings , 2003, The Lancet.

[3]  R. Brooks,et al.  Relaxometry and magnetometry of the MR contrast agent MION‐46L , 1999, Magnetic resonance in medicine.

[4]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[5]  T. S. St. Pierre,et al.  Organ-specific crystalline structures of ferritin cores inβ-thalassemia/hemoglobin E , 2005, Biology of Metals.

[6]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[7]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[8]  K. Ehlers,et al.  Beta thalassemia and heart disease: three decades of gradual progress. , 1985, Transactions of the American Clinical and Climatological Association.

[9]  D. Weatherall,et al.  Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.

[10]  T. S. St. Pierre,et al.  Proton transverse relaxation rate (R2) images of iron‐loaded liver tissuepping local tissue iron concentrations with MRI , 2003 .

[11]  F. Blei,et al.  Chelation therapy and cardiac status in older patients with thalassemia major. , 1990, The American journal of pediatric hematology/oncology.

[12]  A. Tanimoto,et al.  Relaxation effects of clustered particles , 2001, Journal of magnetic resonance imaging : JMRI.

[13]  T. Ur,et al.  Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. , 1997 .

[14]  P. Greenberg,et al.  Major hematologic diseases in the developing world- new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. , 2001, Hematology. American Society of Hematology. Education Program.

[15]  D. Fitchett,et al.  Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. , 1980, Cardiovascular research.

[16]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[17]  T. S. St. Pierre,et al.  Single spin‐echo proton transverse relaxometry of iron‐loaded liver , 2004, NMR in biomedicine.

[18]  K. Ehlers,et al.  LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR * , 1980, Annals of the New York Academy of Sciences.

[19]  T. S. St. Pierre Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. , 2003, Lancet.

[20]  Mark A Westwood,et al.  Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.

[21]  B. Gersh,et al.  Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. , 1987, Journal of the American College of Cardiology.

[22]  Gary M Brittenham,et al.  Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. , 2003, The Journal of laboratory and clinical medicine.

[23]  J. Marx,et al.  The Amount of Ferritin and Hemosiderin in the Livers of Patients with Iron‐Loading Diseases , 2007, Hepatology.

[24]  Y. Kuryshev,et al.  Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. , 1999, Circulation.

[25]  M. N. Levy,et al.  Bimodal cardiac dysfunction in an animal model of iron overload. , 2002, The Journal of laboratory and clinical medicine.

[26]  R. Engelhardt,et al.  Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.

[27]  D. Tsiapras,et al.  Heart failure in beta thalassemia: a 5-year follow-up study. , 2001, The American journal of medicine.

[28]  M. Bock,et al.  Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: Assessment using T*2 and T1 measurements , 1999, Magnetic resonance in medicine.

[29]  M. F. Khan,et al.  Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. , 1997, Journal of toxicology and environmental health.

[30]  N. Olivieri,et al.  Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. , 1996, The Canadian journal of cardiology.

[31]  B. Rosen,et al.  Microscopic susceptibility variation and transverse relaxation: Theory and experiment , 1994, Magnetic resonance in medicine.

[32]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[33]  W. Edwards,et al.  Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. , 1989, Journal of the American College of Cardiology.

[34]  W. Roberts,et al.  Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.

[35]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[36]  E. T. Adams,et al.  Morphologic Investigations of the Guinea Pig Model of Iron Overload , 1993, Toxicologic pathology.

[37]  M. N. Levy,et al.  Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. , 2003, The Journal of laboratory and clinical medicine.

[38]  M. Jessup,et al.  Diagnosis and Management of Iron‐induced Heart Disease in Cooley's Anemia , 1998, Annals of the New York Academy of Sciences.

[39]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[40]  D. Weatherall Thalassemia in the Next Millennium: Keynote Address a , 1998, Annals of the New York Academy of Sciences.

[41]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[42]  Huaqing Zhao,et al.  1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. , 2005, Radiology.

[43]  A. Hoffbrand,et al.  High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. , 1990, Acta haematologica.

[44]  D. Pennell,et al.  A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.

[45]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.